Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2023-02-27 Report Publication Anno…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
PUBLICATION OF THE 2022 ANNUAL RESULTS OF AN OVERSEAS SUBSIDIARY CONTROLLED BY YANKUANG ENERGY GROUP COMPANY LIMITED
Report Publication Announcement Classification · 95% confidence The document is an announcement by Yankuang Energy Group Company Limited regarding the publication of the 2022 annual results of its overseas subsidiary, Yancoal Australia. It references the subsidiary's annual results announcement and provides summary financial data, but it does not contain the full annual report or detailed financial statements itself. The document is relatively short (2756 characters) and directs readers to the full announcement on the ASX and HKEX websites. This fits the pattern of a Report Publication Announcement (RPA), which notifies stakeholders that a report has been published elsewhere rather than presenting the full report itself.
2023-02-27 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCED ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION BY THE EUROPEAN MEDICINES AGENCY FOR SUGEMALIMAB IN METASTATIC SQUAMOUS AND NON-SQUAMOUS NON-SMALL CELL LUNG
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the acceptance of a Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for a drug called sugemalimab. It discusses clinical trial data, regulatory milestones, and strategic collaborations. There are no financial statements, no detailed financial performance data, no management discussion of financial results, and no mention of an annual or interim report. The document is an announcement of a regulatory and marketing milestone rather than a financial report or management report. It is not a certification or a proxy statement, nor does it relate to share transactions or capital changes. The content fits best with a Regulatory Filings (RNS) category, which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length (9296 characters) and content confirm it is a full announcement, not a brief report publication notice. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-02-23 English
DOCUMENTS ON DISPLAY - RULES OF RESTRICTED SHARE AWARD SCHEME
Governance Information Classification · 95% confidence The document is titled 'Rules of Restricted Share Award Scheme' and contains detailed provisions about definitions, purposes, administration, and operation of a restricted share award scheme for CStone Pharmaceuticals. It is a comprehensive set of rules governing a share award plan, including terms like 'Board', 'Trustee', 'Eligible Participants', 'Grant Date', and references to the Hong Kong Stock Exchange Listing Rules. This document is not an announcement, report, or financial statement but a governance document detailing internal rules related to share awards. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2023-02-20 English
DOCUMENTS ON DISPLAY - RULES OF EMPLOYEE EQUITY PLAN
Capital/Financing Update Classification · 95% confidence The document is titled 'Amended Employee Equity Plan' and contains detailed rules and definitions related to an employee equity plan, including terms like 'Grant Date', 'Subscription Price', 'Vesting Schedule', and 'Option Shares'. It is a comprehensive plan document outlining the terms and conditions of an employee stock option plan, including eligibility, administration, and corporate events affecting the plan. There is no indication that this is a report of financial results, audit, or regulatory filing. It is not an announcement or summary but the actual plan document itself. This type of document fits best under the category of Capital/Financing Update (CAP), as employee equity plans relate to capital structure and financing arrangements through equity incentives.
2023-02-20 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2023-02-20 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and/or share buybacks for CStone Pharmaceuticals. It includes detailed information about a share allotment and issue of new shares under a general mandate, with specifics on the number of shares, issue price, and dates. The document references compliance with listing rules of the Stock Exchange of Hong Kong and confirms authorization by the board of directors. This type of document is a regulatory disclosure about share capital changes, specifically share issues, rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive disclosure data. The document fits the definition of a Share Issue/Capital Change announcement (SHA).
2023-02-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.